NRAS and neoplasm: Indeed, we showed that targeting NRAS via either molecular knock-down or pharmacological inhibition with lonafarnib did not affect pAKT signalling neither in vitro nor in vivo (Supplementary Fig. 10A, B), suggesting that lonafarnib could overcome this feedback activation and result in a stronger anti-tumour effect.